The choice between PMMA and foldable intraocular lenses is not simply a question of technology versus tradition. It is a clinical decision shaped by incision requirements, posterior capsule opacification risk, visual outcome expectations, available infrastructure, and — critically — patient affordability. This guide gives you everything you need to make that choice with evidence.

A Brief History — PMMA and the Birth of Modern IOLs

The intraocular lens story begins in 1949 with Sir Harold Ridley at St Thomas' Hospital, London. Ridley observed that WWII pilots with PMMA cockpit fragments in their eyes did not show the inflammatory rejection response expected — the material was inert. From this observation he developed the first implantable IOL, made from polymethylmethacrylate. For four decades, PMMA was the only IOL material available.

PMMA — polymethylmethacrylate — is a rigid, optically clear acrylic polymer with a refractive index of approximately 1.49 and a long track record of intraocular biocompatibility. Its rigidity, however, requires the surgeon to enlarge the incision to the full diameter of the optic — typically 5–6mm — to allow implantation. This constraint drove the development of foldable IOL materials in the 1980s.

Material Science — What Makes Each IOL Different

Understanding the clinical differences between PMMA and foldable IOLs starts with understanding their polymer chemistry.

The Clinical Evidence — Key Studies

The most important comparative data comes from a 2014 prospective, randomised controlled trial by Haripriya et al., involving 1,200 patients at the Aravind Eye Care System in India — one of the highest-volume cataract surgical systems in the world and therefore a uniquely valid setting for this comparison.

Key findings from the 1,200-patient RCT:

• Visual outcomes at 1 year: UCVA 6/18 or better in 90.3% (foldable) vs 94.3% (PMMA) — no clinically significant difference (RR 0.96, 95% CI 0.92–0.99)
• PCO at 12 months: 23.3% (foldable) vs 36.1% (PMMA) — significantly lower with foldable (p < 0.05)
• Cost: Foldable IOL cost was 8× higher than PMMA in this study (USD 20.63 vs USD 2.50)
• Surgical time: No significant difference between groups
• Surgically-induced astigmatism: Lower with foldable (smaller incision), with differences more pronounced at 6 weeks — resolved at 1 year

Full Comparison — PMMA vs Foldable vs Hydrophobic

The following table synthesises the clinical, surgical, and practical differences across the three main IOL types available in Agaaz Ophthalmics' portfolio.

PCO — The Most Important Long-Term Difference

Posterior capsule opacification (PCO) — colloquially known as "secondary cataract" — is the most clinically significant long-term complication difference between PMMA and foldable IOLs. It is caused by the migration and proliferation of residual lens epithelial cells (LECs) across the posterior capsule following surgery.

Three factors determine PCO risk, in order of importance:

1. Optic edge design: A square, truncated optic edge creates a physical barrier to LEC migration — the most powerful PCO-prevention strategy regardless of material. Both modern PMMA (OP-LENS) and foldable designs can incorporate this.
2. Material biointeraction: Hydrophobic acrylic creates adhesion between the posterior capsule and the lens optic, reducing the space through which LECs can migrate. This explains the significantly lower PCO rates with hydrophobic designs.
3. In-the-bag placement: IOLs placed in the capsular bag — not the sulcus — show lower PCO rates due to better capsular apposition.

Surgical Protocol — Step by Step

The surgical workflow differs meaningfully between PMMA and foldable IOL implantation, primarily at the incision construction and delivery steps.

1. 01
   Incision construction — the critical fork

   For foldable IOL: construct a 2.5–3.2mm clear corneal incision. For PMMA: construct a 5–6mm sclerocorneal tunnel or clear corneal incision. The sclerocorneal approach is preferred for PMMA to reduce direct corneal stress from the larger incision. All other steps — capsulorhexis, hydrodissection, phaco — are identical.

2. 02
   OVD — identical for both IOL types

   Fill the anterior chamber and capsular bag with OVD prior to IOL insertion. For foldable IOL implantation, cohesive OVD (e.g., PURE-HYAL by Agaaz) is preferred for superior capsular bag expansion. For PMMA, either cohesive or dispersive OVD provides adequate working space given the larger incision.

3. 03
   Foldable IOL: injector delivery

   Load the foldable IOL into the injector cartridge (or use a pre-loaded system). Advance the injector tip to the incision and inject the IOL into the capsular bag using controlled, smooth plunger pressure. Allow haptics to unfold spontaneously — do not rush haptic deployment. OP-FOLD AS and OP-VIEW AS are designed for smooth injector delivery with minimal follower use.

4. 04
   PMMA IOL: forceps delivery through enlarged wound

   Enlarge the incision to 5–6mm. Using McPherson or Kelman-McPherson forceps, grasp the OP-LENS IOL at the optic-haptic junction and fold/slide into the capsular bag. Position the inferior haptic first, then dial the superior haptic into the bag. For single-piece PMMA, maintain the in-the-bag position carefully.

5. 05
   Remove OVD and intracameral prophylaxis

   Complete bimanual I/A to remove all OVD. Then administer intracameral moxifloxacin (e.g., MOXGUARD by Agaaz) as per prophylaxis protocol. Hydrate wounds. PMMA requires suturing of the enlarged incision in many cases — add 10-0 nylon if the wound does not self-seal.

Patient Selection — When to Choose Which

The Agaaz IOL Portfolio

Agaaz Ophthalmics manufactures all three IOL material categories — giving surgeons and distributors a single-source supply chain for the complete IOL tray, from cost-effective PMMA to premium hydrophobic foldable.

Related Clinical Guides

Clinical Takeaways

• Visual acuity at 1 year is equivalent between PMMA and foldable IOLs in experienced hands — the 1,200-patient RCT confirmed no clinically significant difference.
• PCO rates are significantly lower with foldable IOLs — 23.3% vs 36.1% at 12 months. Over 3–5 years, this gap widens, with meaningful implications for YAG laser burden in the patient pathway.
• Incision size is the dominant practical difference — foldable IOLs require 2.5–3.2mm vs 5–6mm for PMMA, resulting in less surgically-induced astigmatism and faster recovery.
• PMMA remains clinically valid and essential — in high-volume, cost-sensitive settings, it provides excellent outcomes at 8× lower cost. OP-LENS by Agaaz maintains a square-edge design to minimise PCO within the PMMA category.
• Hydrophobic acrylic (OP-VIEW AS) has the lowest PCO rates and is the only material platform compatible with premium IOLs (EDOF, trifocal, toric).
• Hydrophilic acrylic (OP-FOLD AS) has the best uveal biocompatibility — preferred in uveitic cataracts, compromised endothelium, and paediatric cases.
• Square-edge optic design matters more than material for PCO prevention — both OP-LENS and OP-VIEW AS incorporate this design feature.